# Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer

> **NCT01669239** · PHASE2 · COMPLETED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 83 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT01669239
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01669239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01669239, "Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01669239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*